A number of research firms have changed their ratings and price targets for Zoetis (NYSE: ZTS):

  • 11/28/2016 – Zoetis was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Zoetis reported better-than-expected third-quarter results, wherein earnings surpassed estimates by a wide margin. It also managed to beat revenue estimates, albeit marginally. Zoetis’ companion animal business continued to perform well in the reported quarter. Zoetis has once again raised its earnings outlook for 2016 on the back of a strong year-to-date performance, which is encouraging. Further, its efforts on boosting operational efficiency bode well. We are positive on Zoetis’ recent acquisition of Scandinavian Micro Biodevices, which should expand its offerings in the growing veterinary diagnostics segment of the animal health market. We expect to see more of such acquisitions/deals at the company as it continues to focus on acquiring complementary businesses and products.However, performance of the livestock business is concerning. Headwinds remain in the form of disease outbreaks and stiff competition in the animal health space.”
  • 11/25/2016 – Zoetis was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $56.00 price target on the stock. According to Zacks, “Zoetis reported better-than-expected third-quarter results, wherein earnings surpassed estimates by a wide margin. It also managed to beat revenue estimates, albeit marginally. Zoetis’ companion animal business continued to perform well in the reported quarter.Zoetis has once again raised its earnings outlook for 2016 on the back of a strong year-to-date performance, which is encouraging. Further, its efforts on boosting operational efficiency bode well. We are positive on Zoetis’ recent acquisition of Scandinavian Micro Biodevices, which should expand its offerings in the growing veterinary diagnostics segment of the animal health market. We expect to see more of such acquisitions/deals at the company as it continues to focus on acquiring complementary businesses and products.However, performance of the livestock business is concerning. Headwinds remain in the form of disease outbreaks and stiff competition in the animal health space.”
  • 11/21/2016 – Zoetis was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Zoetis reported better-than-expected third-quarter results, wherein earnings surpassed estimates by a wide margin. It also managed to beat revenue estimates, albeit marginally. Zoetis’ companion animal business continued to perform well in the reported quarter.Zoetis has once again raised its earnings outlook for 2016 on the back of a strong year-to-date performance, which is encouraging. Further, its efforts on boosting operational efficiency bode well. We are positive on Zoetis’ recent acquisition of Scandinavian Micro Biodevices, which should expand its offerings in the growing veterinary diagnostics segment of the animal health market. We expect to see more of such acquisitions/deals at the company as it continues to focus on acquiring complementary businesses and products.However, performance of the livestock business is concerning. Headwinds remain in the form of disease outbreaks and stiff competition in the animal health space.”
  • 11/16/2016 – Zoetis was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $55.00 price target on the stock. According to Zacks, “Zoetis reported better-than-expected third-quarter results, wherein earnings surpassed estimates by a wide margin. It also managed to beat revenue estimates, albeit marginally. Zoetis’ companion animal business continued to perform well in the reported quarter.Zoetis has once again raised its earnings outlook for 2016 on the back of a strong year-to-date performance, which is encouraging. Further, its efforts on boosting operational efficiency bode well. We are positive on Zoetis’ recent acquisition of Scandinavian Micro Biodevices, which should expand its offerings in the growing veterinary diagnostics segment of the animal health market. We expect to see more of such acquisitions/deals at the company as it continues to focus on acquiring complementary businesses and products.However, performance of the livestock business is concerning. Headwinds remain in the form of disease outbreaks and stiff competition in the animal health space.”
  • 11/15/2016 – Zoetis was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Zoetis reported better-than-expected third-quarter results, wherein earnings surpassed estimates by a wide margin. It also managed to beat revenue estimates, albeit marginally. Zoetis’ companion animal business continued to perform well in the reported quarter.Zoetis has once again raised its earnings outlook for 2016 on the back of a strong year-to-date performance, which is encouraging. Further, its efforts on boosting operational efficiency bode well. We are positive on Zoetis’ recent acquisition of Scandinavian Micro Biodevices, which should expand its offerings in the growing veterinary diagnostics segment of the animal health market. We expect to see more of such acquisitions/deals at the company as it continues to focus on acquiring complementary businesses and products.However, performance of the livestock business is concerning. Headwinds remain in the form of disease outbreaks and stiff competition in the animal health space.”
  • 11/7/2016 – Zoetis was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $56.00 price target on the stock. According to Zacks, “Zoetis reported better-than-expected third-quarter results, wherein earnings surpassed estimates by a wide margin. It also managed to beat revenue estimates, albeit marginally. Zoetis’ companion animal business continued to perform well in the reported quarter.Zoetis has once again raised its earnings outlook for 2016 on the back of a strong year-to-date performance, which is encouraging. Further, its efforts on boosting operational efficiency bode well. We are positive on Zoetis’ recent acquisition of Scandinavian Micro Biodevices, which should expand its offerings in the growing veterinary diagnostics segment of the animal health market. We expect to see more of such acquisitions/deals at the company as it continues to focus on acquiring complementary businesses and products.However, performance of the livestock business is concerning. Headwinds remain in the form of disease outbreaks and stiff competition in the animal health space.”
  • 11/3/2016 – Zoetis had its “hold” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $53.00 price target on the stock.
  • 10/16/2016 – Zoetis had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a $63.00 price target on the stock.
  • 10/13/2016 – Zoetis was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Zoetis, one of the leading global animal health companies, is focused on both livestock and companion animals. Performance of the livestock business is concerning. Headwinds remain in the form of disease outbreaks and stiff competition in the animal health space. Zoetis continued to witness a decline in the U.S. sales of swine products in the second quarter of 2016 due to increased competition. Meanwhile, sales of poultry products are declining globally due to competitive pressures. Pipeline setbacks remain a concern as well. However, the company’s companion animal business should continue to perform well. Further, Zoetis’ efforts at boosting operational efficiency bode well. We are positive on Zoetis’ recent acquisition of Scandinavian Micro Biodevices, which should expand its offerings in the growing veterinary diagnostics segment of the animal health market. We expect to see more of such acquisitions/deals at the company.”
  • 10/12/2016 – Zoetis had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $58.00 price target on the stock.
  • 10/6/2016 – Zoetis was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Zoetis, one of the leading global animal health companies, is focused on both livestock and companion animals. The company’s companion animal business should continue to perform well. Zoetis' raised guidance for 2016, on the back of a strong performance in the first half of the year, is encouraging. Further, Zoetis’ efforts at boosting operational efficiency bode well. We are positive on Zoetis’ recent acquisition of Scandinavian Micro Biodevices, which should expand its offerings in the growing veterinary diagnostics segment of the animal health market. We expect to see more of such acquisitions/deals at the company as it continues to focus on the strategy of acquiring complementary businesses and products. However, performance of the livestock business is concerning. Moreover, headwinds remain in the form of disease outbreaks and stiff competition in the animal health space. Pipeline setbacks remain a concern as well.”

Zoetis Inc. (NYSE:ZTS) traded up 0.588% during mid-day trading on Tuesday, reaching $50.445. The company’s stock had a trading volume of 1,593,873 shares. The company’s 50-day moving average price is $50.03 and its 200 day moving average price is $49.67. Zoetis Inc. has a 52 week low of $38.26 and a 52 week high of $53.14. The firm has a market capitalization of $24.91 billion, a price-to-earnings ratio of 36.370 and a beta of 1.05.

Zoetis (NYSE:ZTS) last posted its earnings results on Wednesday, November 2nd. The company reported $0.52 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.46 by $0.06. Zoetis had a net margin of 14.10% and a return on equity of 72.96%. The firm earned $1.20 billion during the quarter, compared to the consensus estimate of $1.22 billion. During the same quarter last year, the firm earned $0.50 EPS. The firm’s revenue for the quarter was up 2.2% on a year-over-year basis. On average, equities analysts forecast that Zoetis Inc. will post $1.94 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Thursday, November 3rd will be given a $0.095 dividend. The ex-dividend date is Tuesday, November 1st. This represents a $0.38 annualized dividend and a yield of 0.76%. Zoetis’s dividend payout ratio is presently 27.54%.

In other news, insider Heidi C. Chen sold 32,097 shares of Zoetis stock in a transaction on Thursday, September 1st. The shares were sold at an average price of $50.98, for a total transaction of $1,636,305.06. Following the completion of the sale, the insider now directly owns 46,060 shares of the company’s stock, valued at approximately $2,348,138.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Kristin C. Peck sold 10,092 shares of Zoetis stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $49.55, for a total transaction of $500,058.60. Following the sale, the insider now directly owns 22,768 shares of the company’s stock, valued at $1,128,154.40. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by company insiders.

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

5 Day Chart for NYSE:ZTS

Receive News & Ratings for Zoetis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc and related companies with MarketBeat.com's FREE daily email newsletter.